Clinical Trials
39 trialsA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
OrigAMI-2
Janssen Research & Development, LLC
OrigAMI-3
Janssen Research & Development, LLC
LUCERNA
Astellas Pharma Inc
MOUNTAINEER-03
Seagen Inc.
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
RASolute 305
Revolution Medicines, Inc.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
KANDLELIT-012
Merck Sharp & Dohme LLC
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Beacon-BTC
J-Pharma Co., Ltd.
NEO-RT
Canadian Cancer Trials Group
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
HARMONi-GI3
Summit Therapeutics
LAP100
NRG Oncology
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Akeso
FOBEAR
Sun Yat-sen University
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Universitätsmedizin Mannheim
AIO-KRK-0418
Charite University, Berlin, Germany
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
LIBImAb
Azienda USL Reggio Emilia - IRCCS
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
OSCAR
Federation Francophone de Cancerologie Digestive
PANThEON
Gruppo Oncologico del Nord-Ovest
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy
Tanta University
NEEDS
Karolinska University Hospital
PREVENT
Krankenhaus Nordwest
HAIC
Sun Yat-sen University
IMPROVE-2
National Cancer Institute, Naples
Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer
Fudan University
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School